ClinicalTrials.gg
Status unknownNCT03026881Updated Mar 7, 2017

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

A Phase 1 interventional study of Fluzoparib and Apatinib in Recurrent and Metastatic Gastric Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-07.

Primary conditionStomach NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Stomach Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Stomach Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.

Planned enrollment
48th of 57
24 · median 47
Started
2017
with 9 others
Phase 1
4 of 57
1 open now
Registered
13th of 57
by date
Lead sponsor
5 of 57
Jiangsu HengRui Medicine Co., Ltd.

Among the 57 studies testing apatinib in Stomach Neoplasms, this one is the 48th largest by planned enrollment, is one of 10 that started in 2017, is one of 4 in phase 1, and was the 13th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing apatinib in Stomach Neoplasms, or all of them as a file.
02

Study summary

Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor; Apatinib is an oral selective VEGFR inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of Fluzoparib in combination with apatinib and paclitaxel and to see how well this three drugs work together in the treatment of patients with recurrent and metastatic gastric cancer who progress following first-line therapy. The safety and efficacy of fluzoparib in combination with apatinib and paclitaxel will be explored.

03

Conditions studied

  • Recurrent and Metastatic Gastric Cancer

Browse trials for

Keywords

  • PARP inhibitor
  • VEGFR inhibitor
  • Combination therapy
  • Gastric cancer
04

In context

Stomach Neoplasms Reclassified

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

This study's planned enrollment of 24 is below the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Compared within Stomach Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of 0 to 1.
  • of more than 12 weeks.
  • or cytologically confirmed gastric adenocarcinoma( adenocarcinoma of the gastroesophageal junction included).
  • Recurrent or gastric cancer that has progressed following -therapy.
  • At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline
  • Subjects who have overall good overall general condition.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Subjects who received any previous treatment with any PARP inhibitors.
  • Subjects who received any previous treatment with any taxanes.
  • More than one prior chemotherapy regimen for the treatment of gastric cancer in the or recurrent setting.
  • Less than 4 weeks from the last clinical trial.
  • Less than 2 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy.
  • Unstable hypertension.
  • Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption.
  • Subjects with .
  • Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
  • Subjects with a known to fluzoparib, apatinib, paclitaxel or any of the of the product.
  • Ongoing infection (determined by investigator).
  • History of immunodeficiency, including -positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
  • Subjects who can not interrupt the using of the drugs that may cause during study.
  • Pregnant or breast-feeding women.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Fluzoparib + Apatinib + Paclitaxel

    Drug: Fluzoparib · Drug: Apatinib · Drug: Paclitaxel

Interventions

  • Fluzoparib either at 20,30,40mg twice daily,capsule oral.

    Also known as: SHR3162

  • Oral

  • Intravenous injection

07

What researchers measure

Primary outcomes

  1. DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.

    DLT and safety defined by CTC version 4.0

    Time frame: through study completion, an average of 6 months

Secondary outcomes

  1. Best of ORR

    Time frame: through study completion, an average of 6 months

  2. Overall Response Rate (ORR)

    Time frame: through study completion, an average of 6 months

  3. Disease Control Rate (DOR)

    Time frame: through study completion, an average of 6 months

  4. Time to Progression (TTP)

    Time frame: From date of enrollment until the date of first objective progression, assessed up to 9 months

  5. Progression Free Survival (PFS)

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, an average of 6 months

  6. Maximum plasma concentration (Cmax)

    Time frame: Up to 33 days

  7. Terminal half life (t1/2)

    Time frame: Up to 33 days

  8. Area under the plasma concentration-time curve (AUC)

    Time frame: Up to 33 days

  9. Volume of distribution (V/F)

    Time frame: Up to 33 days

  10. Plasma Clearance (CL/F)

    Time frame: Up to 33 days

08

Study locations

1 of 1 sites recruiting
  • The Affiliated Hospital of Military Medical Sciences
    Beijing, Beijing 100039, China
    Recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2017, a primary completion of Apr 2018 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2016
First posted
Jan 20, 2017
Start
Jan 2017
Primary completionEst.
Apr 2018
CompletionEst.
Jun 2018
Last update
Mar 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03026881
Collaborators
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Responsible party
Sponsor
First posted
Jan 20, 2017
Start date
Jan 2017
Primary completion
Apr 2018 (estimated)
Completion
Jun 2018 (estimated)
Last update
Mar 7, 2017

Study contacts

Jianming Xu, MD
Contact
jmxu2003@yahoo.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluzoparib · Apatinib

Start the discussion